#USA #Atrial Fibrillation #Marseille #Volta Medical #AF-Xplorer II

Volta Medical Launches AF-Xplorer II in the U.S.

On November 5, 2025, Volta Medical, a pioneering company in health technology, revealed the introduction of its innovative AF-Xplorer II system designed to advance the treatment of complex atrial fibrillation (AF) in the United States. This groundbreaking artificial intelligence (AI) solution aims to enhance patient care greatly by simplifying the real-time assessment process for electrophysiologists dealing with AF.

Innovations and Enhancements

The AF-Xplorer II is a successor to the original model, incorporating several important improvements that enhance its functionality:

• - High Stability Analysis: This feature provides physicians with a reliable method to pinpoint areas of interest during procedures, allowing them to concentrate on the most critical aspects of their work.
• - Expanded Catheter Compatibility: The system now supports analysis of signals from Medtronic's Sphere-9™ mapping and ablation catheter, widening the treatment options for physicians.
• - Integration with GE HealthCare's CardioLab™ AI Recording System: This integration facilitates a smoother workflow for medical professionals during procedures.

The AF-Xplorer II is expected to substantially increase the efficiency of electrophysiology procedures, and after obtaining CE Mark approval earlier in Europe, it has already started to make an impact in clinical practices.

Commitment to Patient Care

The CEO and co-founder of Volta Medical, Théophile Mohr Durdez, highlighted the company's mission to make a significant difference in the lives of those afflicted by complex AF. He acknowledged that despite the advances in technology and procedural innovations over the years, the efficacy of treatments has largely stagnated. He expressed confidence that AF-Xplorer II stands as a significant advancement both in the specificity of its algorithm and its interoperability with existing systems.

Dr. Devi Nair, a prominent electrophysiologist and Director of Cardiac Electrophysiology at St. Bernard's Heart and Vascular Center, emphasized that this next-generation technology could potentially transform the approach to complicated atrial fibrillation procedures. He noted the importance of improved consistency in outcomes, particularly for patients who historically have faced significant challenges in treatment.

Impact on Atrial Fibrillation Treatment

The introduction of AF-Xplorer II is a strategic step for Volta Medical as it strives to enhance AF care by providing practitioners with intelligent, real-time data during complex ablation procedures. The benefits of advanced AI technologies are now accessible to patients and healthcare providers across the U.S.

Understanding Atrial Fibrillation

Atrial fibrillation, characterized by irregular heartbeats or arrhythmias, poses severe risks including blood clots, strokes, and heart failure. According to the American Heart Association, approximately 33 million individuals around the world suffer from AF. Alarmingly, untreated AF not only doubles the risk of heart-related deaths but also significantly increases the likelihood of stroke, yet many individuals remain unaware of the condition's severity.

About Volta Medical

Founded in 2016 in Marseille, France, Volta Medical aims to revolutionize the treatment of complex cardiac arrhythmias using AI. Their flagship product, the AF-Xplorer II, serves as a comprehensive digital companion for electrophysiologists, facilitating real-time identification of spatio-temporal dispersed electrograms during AF and atrial tachycardia procedures. The system is noted for its versatility and compatibility with leading AF mapping and recording systems. Both FDA 510(k) cleared and CE Marked, AF-Xplorer II is positioned to transform the landscape of AF treatment.

In addition to developing advanced technologies, Volta Medical has initiated the AI for Persistent AF Care program, which connects patients, caregivers, and healthcare providers to valuable resources regarding AF and AI-driven treatments. For further details, visit www.aiforafib.com.